Half-Day Event:  Doing Life Sciences Deals in 2024 - Licensing, M&A, and More (Boston)

Panels include Structuring Your Life Sciences Transaction - Licensing vs. M&A vs. Asset Sale and Key Issues for Your Biopharma Licensing Deal - IP, Scientific, and More.

Learning Outcomes:

• Deal trends
• Considerations when structuring your deal
• Should you do an M&A vs. license vs. asset sale – considerations for deal
• Strategies for doing a deal with big pharma
• What does big pharma look for in a deal structure?
• Is licensing a way to an M&A deal with big pharma?
• Key non-economic issues for your biopharma licensing deal
• IP – how does big pharma diligence it, and how can a biotech satisfy a big pharma
• Scientific rigor – How does a big pharma evaluate your science?
• How do these key issues play into your license agreement?
• How do you run an efficient and productive diligence process?
• How should you time your licensing deal with your data readout?

Panel 1 - 2:30-3:30 - Structuring Your Life Sciences Transaction: Licensing vs. M&A vs. Asset Sale

Speakers:
Jeff Caravella, Business Development, Interventional Oncology, Johnson & Johnson
Andy Meyerson, Managing Director, Locust Walk
Veronica Miller, Executive Director, Business Development, Astria Therapeutics, Inc.
Jonathan Kiburz, Vice President, Business Development Transactions, GSK
Moderator: Cheryl Reicin, International Chair, Life Sciences, Mintz

Panel 2 - 3:45-4:45 - Key Issues for Your Biopharma Licensing Deal - IP, Scientific Diligence, and More

Speakers:
Fanny Cavalie, Chief Strategy and Business Operations Officer, Foghorn Therapeutics
Beatriz Gadala-Maria, Senior Director, Transactions, Business Development, Early Stage Oncology Transactions, AstraZeneca
Imran Nasrullah, Vice President & Head, Collaborate2Cure Hub, US, Business Development & Licensing, Bayer Pharmaceuticals
Moderator: Adam Falconi, Attorney, Mintz

Members: $39
Non-Members: $69